Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination

Front Immunol. 2023 Aug 3:14:1231276. doi: 10.3389/fimmu.2023.1231276. eCollection 2023.

Abstract

The kinetics of Fc-mediated functions following SARS-CoV-2 infection or vaccination in people living with HIV (PLWH) are not known. We compared SARS-CoV-2 spike-specific Fc functions, binding, and neutralization in PLWH and people without HIV (PWOH) during acute infection (without prior vaccination) with either the D614G or Beta variants of SARS-CoV-2, or vaccination with ChAdOx1 nCoV-19. Antiretroviral treatment (ART)-naïve PLWH had significantly lower levels of IgG binding, neutralization, and antibody-dependent cellular phagocytosis (ADCP) compared with PLWH on ART. The magnitude of antibody-dependent cellular cytotoxicity (ADCC), complement deposition (ADCD), and cellular trogocytosis (ADCT) was differentially triggered by D614G and Beta. The kinetics of spike IgG-binding antibodies, ADCC, and ADCD were similar, irrespective of the infecting variant between PWOH and PLWH overall. However, compared with PWOH, PLWH infected with D614G had delayed neutralization and ADCP. Furthermore, Beta infection resulted in delayed ADCT, regardless of HIV status. Despite these delays, we observed improved coordination between binding and neutralizing responses and Fc functions in PLWH. In contrast to D614G infection, binding responses in PLWH following ChAdOx-1 nCoV-19 vaccination were delayed, while neutralization and ADCP had similar timing of onset, but lower magnitude, and ADCC was significantly higher than in PWOH. Overall, despite delayed and differential kinetics, PLWH on ART develop comparable responses to PWOH, supporting the prioritization of ART rollout and SARS-CoV-2 vaccination in PLWH.

Keywords: ChAdOx1 nCov-19 vaccination; Fc effector functions; SARS-CoV-2 infection; humoral response kinetics; neutralization; people living with HIV (PLWH).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Neutralizing* / blood
  • Antibodies, Neutralizing* / immunology
  • Antibodies, Viral* / blood
  • Antibodies, Viral* / immunology
  • Antibody-Dependent Cell Cytotoxicity*
  • COVID-19* / immunology
  • COVID-19* / prevention & control
  • ChAdOx1 nCoV-19 / immunology
  • ChAdOx1 nCoV-19 / therapeutic use
  • Female
  • HEK293 Cells
  • HIV Infections* / blood
  • HIV Infections* / immunology
  • Humans
  • Immunity, Humoral
  • Immunoglobulin Fc Fragments* / blood
  • Immunoglobulin Fc Fragments* / immunology
  • Immunoglobulin G / blood
  • Immunoglobulin G / immunology
  • Male
  • Middle Aged
  • Spike Glycoprotein, Coronavirus* / immunology
  • Vaccination

Substances

  • Immunoglobulin Fc Fragments
  • ChAdOx1 nCoV-19
  • Immunoglobulin G
  • spike protein, SARS-CoV-2
  • Spike Glycoprotein, Coronavirus
  • Antibodies, Neutralizing
  • Antibodies, Viral